TYGRIS: TYSABRI Global Observational Program in Safety
Phase of Trial: Phase IV
Latest Information Update: 17 Sep 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TYGRIS
- Sponsors Biogen
- 08 Sep 2016 According to Biogen media release, data from this trial will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.